StockTok Wire

StockTok’s daily headlines and financial news driving the broader market

Cyclacel Pharmaceuticals Reviews 2022 Achievements and Announces Key Business Objectives for 2023

– Determination of Recommended Phase 2 Dose and Start of Phase 2 in 1Q 2023 for Oral Fadraciclib – – 2/3 Partial Responses in Lymphoma and 11/15 Stable Disease in Advanced Solid Tumors– – Expecting Key Data Readouts for Oral Fadraciclib in 2023– – Expecting Preliminary Safety and Efficacy Update for Oral Plogosertib (formerly CYC140) in

Cyclacel Pharmaceuticals Reviews 2022 Achievements and Announces Key Business Objectives for 2023 Read More »

Analysis-Hamas’ tight grip on Gaza complicates plan for lasting peace By Reuters

By Nidal al-Mughrabi CAIRO (Reuters) – In neighbourhoods levelled by 15 months of war with Israel, Hamas officials are overseeing the clearance of rubble in the wake of Sunday’s ceasefire. The group’s gunmen are guarding aid convoys on Gaza’s dusty roads, and its blue-uniformed police once again patrol city streets, sending a clear message: Hamas

Analysis-Hamas’ tight grip on Gaza complicates plan for lasting peace By Reuters Read More »

Barry Callebaut posts lower volumes amid soaring cocoa prices By Reuters

(Reuters) -Chocolate maker and cocoa processor Barry Callebaut on Wednesday reported a lower sales volume than expected for its first quarter, hit by customer-retailer pricing negotiations and delayed orders amidst record high cocoa prices. The Switzerland-based group, which supplies chocolate for Unilever (LON:)’s soon-to-be-spun-off Magnum ice creams and Nestle (NSE:)’s KitKat bars, said its sales

Barry Callebaut posts lower volumes amid soaring cocoa prices By Reuters Read More »

Moderna (MRNA) to Boost mRNA Portfolio With OriCiro Buyout

ModernaMRNAannounced that it entered a definitive agreement to acquire Japan-based OriCiro Genomics (“OriCiro”) for $85 million. The acquisition of OriCiro looks like a strategic fit for Moderna, as the company is focused on expanding and boosting its mRNA-manufacturing capabilities. It expects OriCiro’s proprietary technologies to support its portfolio of mRNA-based therapeutics and vaccines. OriCiro is

Moderna (MRNA) to Boost mRNA Portfolio With OriCiro Buyout Read More »